Syngene International Limited
Valuation (54/100) does the heavy lifting; momentum (3/100) is the drag.
Fair valueStocksWizard rates Syngene International Limited a Sell, scoring 34/100 on our blended model. On 56.1x trailing earnings it sits pricier than the Healthcare median of about 37.6x. It's sitting close to its 52-week low of ₹385.9. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹578.13 implies about 50% upside across 8 analysts. It clears 4 of 13 investability checks, with durability 47, valuation 47 and momentum 3 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹330.56.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-45.80% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell34Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 6.6%
- Pass: Low debt (D/E < 0.5): 0.09x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: 2%
- Fail: Earnings growing: -20%
- Fail: Net margin ≥ 10%: 8.5%
- Fail: Current ratio > 1.5: 1.38
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.22
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter53.0%
- Institutions39.7%
- Public & other7.3%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 6.22.
Opportunities
- Well off its 52-week high — possible mean-reversion.
Bear case
Weaknesses
- Low return on equity (6.6%).
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
About Syngene International Limited
Syngene International Limited operates as a contract research and manufacturing company offering drug discovery and development services across India, the United States, Europe, and internationally. The company delivers discovery chemistry services including synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry, alongside discovery biology services encompassing recombinant DNA engineering.
Syngene International Limited — frequently asked questions
Is Syngene International Limited a buy, hold or sell?
StocksWizard currently rates Syngene International Limited (SYNGENE) a Sell, based on a blended score of 34/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Syngene International Limited's fair value?
Our blended DCF and relative-valuation model estimates Syngene International Limited's fair value at about ₹413.2, versus a current price of ₹385.9 — roughly 7% upside. On that basis the stock looks fairly valued.
Is Syngene International Limited financially healthy?
Syngene International Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Syngene International Limited's share price performed?
Syngene International Limited is down 14% over three months, and last traded at ₹385.9. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.